Dr. Caudle on Upcoming Breast Cancer Trial Results

Abigail S. Caudle, MD
Published: Wednesday, Apr 24, 2013

Abigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, gives an overview of two trials in breast cancer.

Caudle first highlights the ACOSOG Z1071 trial, which aimed to analyze the false-negative rate of a sentinel lymph node dissection after neoadjuvant chemotherapy. This trial closed early with higher than expected accrual, demonstrating physicians' interest.

Further, Caudle is excited to see how the results of the SWOG RxPONDER trial could benefit patients. This trial is evaluating the effect of chemotherapy in patients with breast cancer who have a low to intermediate recurrence score.
Abigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, gives an overview of two trials in breast cancer.

Caudle first highlights the ACOSOG Z1071 trial, which aimed to analyze the false-negative rate of a sentinel lymph node dissection after neoadjuvant chemotherapy. This trial closed early with higher than expected accrual, demonstrating physicians' interest.

Further, Caudle is excited to see how the results of the SWOG RxPONDER trial could benefit patients. This trial is evaluating the effect of chemotherapy in patients with breast cancer who have a low to intermediate recurrence score.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x